Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Irene Kuter, M.D., D.Phil.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. O'Donnell E, Shapiro Y, Comander A, Isakoff S, Moy B, Spring L, Wander S, Kuter I, Shin J, Specht M, Kournioti C, Hu B, Sullivan C, Winters L, Horick N, Peppercorn J. Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Res Treat. 2022 Jun; 193(3):579-587. PMID: 35441995.
    Citations:    Fields:    Translation:Humans
  2. Kuemmel S, Campone M, Loirat D, Lopez RL, Beck JT, De Laurentiis M, Im SA, Kim SB, Kwong A, Steger GG, Adelantado EZ, Duhoux FP, Greil R, Kuter I, Lu YS, Tibau A, Özgüroglu M, Scholz CW, Singer CF, Vega E, Wimberger P, Zamagni C, Couillebault XM, Fan L, Guerreiro N, Mataraza J, Sand-Dejmek J, Chan A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 01 01; 28(1):106-115. PMID: 34615719.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  3. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8. PMID: 33761455.
    Citations: 5     Fields:    
  4. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82. PMID: 30242306; PMCID: PMC6439773.
    Citations: 210     Fields:    Translation:HumansCTClinical Trials
  5. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, Passeri J, Cohen V, Banchs J, Martin RP, Gerszten RE, Scherrer-Crosbie M, Ky B. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015 Sep; 61(9):1164-72. PMID: 26220066; PMCID: PMC4667170.
    Citations: 56     Fields:    Translation:Humans
  6. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, Fei H, Hochberg EP, Abramson JS, Weyman AE, Kuter I, Scherrer-Crosbie M. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol. 2015 Aug 01; 116(3):442-6. PMID: 26071994.
    Citations: 23     Fields:    Translation:Humans
  7. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, Passeri J, Kuter I, Scherrer-Crosbie M. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab. J Am Soc Echocardiogr. 2015 May; 28(5):509-14. PMID: 25772019.
    Citations: 21     Fields:    Translation:Humans
  8. Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30. PMID: 25205424.
    Citations: 6     Fields:    Translation:HumansCells
  9. Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer. 2014 Dec; 14(6):381-9. PMID: 25457991.
    Citations: 27     Fields:    Translation:Humans
  10. Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer. Clin Cancer Res. 2014 Aug 01; 20(15):3962-73. PMID: 24916694; PMCID: PMC4119788.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  11. Knudsen S, Jensen T, Hansen A, Mazin W, Lindemann J, Kuter I, Laing N, Anderson E. Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. PLoS One. 2014; 9(2):e87415. PMID: 24505287.
    Citations: 12     Fields:    Translation:Humans
  12. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 04; 63(8):809-16. PMID: 24291281; PMCID: PMC4286181.
    Citations: 174     Fields:    Translation:Humans
  13. Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers. 2013 Apr 23; 28(1):17-23. PMID: 23015398.
    Citations: 4     Fields:    Translation:HumansCells
  14. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012 Sep 01; 5(5):596-603. PMID: 22744937.
    Citations: 244     Fields:    Translation:Humans
  15. Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012 May; 133(1):237-46. PMID: 22286314.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  16. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011 May 01; 107(9):1375-80. PMID: 21371685; PMCID: PMC3703314.
    Citations: 201     Fields:    Translation:Humans
  17. Kuter I, Anderson E, Emeribe U, Finlay P, Nicholson R, Gee J. Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST). J Clin Oncol. 2009 May 20; 27(15_suppl):e11602. PMID: 27961051.
  18. Come SE, Parker LM, Wulf G, Kuter I, Ryan PD, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer EP. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):1050. PMID: 27961148.
  19. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. PMID: 19047116.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  20. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008 Jun; 112(11):2359-67. PMID: 18361426.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  21. Kuter I, Sapunar F, McCormack P. Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study. J Clin Oncol. 2008 May 20; 26(15_suppl):579. PMID: 27948695.
  22. Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol. 2006 Jun; 186(6):1783-6. PMID: 16714674.
    Citations: 23     Fields:    Translation:Humans
  23. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504. PMID: 16243442.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  24. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, Boucher Y, Powell SN. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol. 2005 Mar 20; 23(9):1951-61. PMID: 15774788.
    Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
  25. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005 Mar; 184(3):868-77. PMID: 15728611.
    Citations: 100     Fields:    Translation:Humans
  26. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7. PMID: 12784331.
    Citations: 246     Fields:    Translation:Humans
  27. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. PMID: 12506169.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  28. Codington JF, Haavik S, Nikrui N, Kuter I, Vassileva C, Zhang H, Matson S, Chen X, Wu Z. Immunologic quantitation of the carcinoma specific human carcinoma antigen in clinical samples. Cancer. 2002 Feb 01; 94(3):803-13. PMID: 11857316.
    Citations: 3     Fields:    Translation:HumansAnimals
  29. Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001 Dec 05; 93(23):1806-11. PMID: 11734597.
    Citations: 41     Fields:    Translation:Humans
  30. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30. PMID: 11352965.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  31. Kuter I. Breast cancer. Oncologist. 2001; 6(4):338-46. PMID: 11524552.
    Citations: 2     Fields:    Translation:Humans
  32. Kuter I. Breast cancer update. Oncologist. 2000; 5(4):285-92. PMID: 10964995.
    Citations:    Fields:    Translation:Humans
  33. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999 Feb; 17(2):485-93. PMID: 10080589.
    Citations: 134     Fields:    Translation:HumansCTClinical Trials
  34. Kuter I. Breast cancer highlights. Oncologist. 1999; 4(4):299-308. PMID: 10476541.
    Citations: 2     Fields:    Translation:Humans
  35. Kaufman JA, Crenshaw WB, Kuter I, Geller SC. Percutaneous placement of a central venous access device via an intercostal vein. AJR Am J Roentgenol. 1995 Feb; 164(2):459-60. PMID: 7839989.
    Citations: 1     Fields:    Translation:Humans
  36. Kuter I, Johnson-Wint B, Beaupre N, Gross J. Collagenase secretion accompanying changes in cell shape occurs only in the presence of a biologically active cytokine. J Cell Sci. 1989 Mar; 92 ( Pt 3):473-85. PMID: 2556413.
    Citations: 3     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Kuter's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (173)
Co-Authors (50)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.